Company intelligence / Profile preview
TregTherapeutics Inc.
North Carolina, United Statestregtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
TregTherapeutics is developing a universal tolerance induction therapy for autoimmune disease using its proprietary TILAC™ platform. The company’s lead program, TREG101, is being prepared for human proof-of-concept studies. The approach aims to demonstrate safety and efficacy in humans before seeking partnerships with larger biopharma companies to advance through later clinical stages and commercialization[1].
- Therapeutic areas
- Immunology
- Modalities
- Immune tolerance induction platform (TILAC™)Linked adjuvant/cytokine conjugate therapy
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Exclusive license from East Carolina University[1]
Beyond the preview
Go deeper on TregTherapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TregTherapeutics Inc..